|Assembly Actions - Lowercase
Senate Actions - UPPERCASE
|May 04, 2021||referred to insurance|
delivered to assembly
|Apr 28, 2021||advanced to third reading|
|Apr 27, 2021||2nd report cal.|
|Apr 26, 2021||1st report cal.730|
|Feb 05, 2021||referred to health|
senate Bill S4532
Current Bill Status - Passed Senate
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
S4532 (ACTIVE) - Details
S4532 (ACTIVE) - Sponsor Memo
BILL NUMBER: S4532 SPONSOR: BROUK TITLE OF BILL: An act to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs PURPOSE OR GENERAL IDEA OF BILL: To help prevent the abuse and diversion of opioid analgesic drugs by ensuring that abuse-deterrent drugs approved by the FDA are accessible to patients and that that insurance coverage does not disadvantage access for patients to drugs approved by the FDA as abuse-deterrent. SUMMARY OF SPECIFIC PROVISIONS: Section 1 adds a new subdivision 11 to section 273 of the public health law to ensure patient access to abuse-deterrent opioid analgesic drugs by requiring that a minimum of one opioid abuse-deterrent opioid anal-
S4532 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4532 2021-2022 Regular Sessions I N S E N A T E February 5, 2021 ___________ Introduced by Sen. BROUK -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Section 273 of the public health law is amended by adding a new subdivision 11 to read as follows: 11. ANY PRIOR AUTHORIZATION REQUIREMENTS FOR OPIOID ANALGESIC AND ANY SERVICE DENIALS MADE PURSUANT THERETO SHALL NOT REQUIRE USE OF OPIOID ANALGESIC DRUG PRODUCTS WITHOUT ABUSE-DETERRENT PROPERTIES BEFORE AUTHORIZING THE USE OF ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCTS. § 2. The insurance law is amended by adding a new section 3216-a to read as follows: § 3216-A. ACCESS TO ABUSE-DETERRENT OPIOID MEDICATIONS. (A) AN INSUR- ANCE CARRIER OR HEALTH PLAN SHALL PROVIDE COVERAGE ON ITS FORMULARY, DRUG LIST OR OTHER LISTS OF SIMILAR CONSTRUCT FOR AT LEAST ONE ABUSE- DETERRENT OPIOID ANALGESICS DRUG PRODUCT PER OPIOID ANALGESICS ACTIVE INGREDIENT. (1) COST-SHARING FOR BRAND NAME ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCTS COVERED PURSUANT TO THIS SECTION SHALL NOT EXCEED THE LOWEST COST-SHARING LEVEL APPLIED TO BRAND NAME NON-ABUSE DETERRENT OPIOID DRUGS COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY. (2) COST-SHARING FOR GENERIC ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCTS COVERED PURSUANT TO THIS SECTION SHALL NOT EXCEED THE LOWEST COST-SHARING LEVEL APPLIED TO GENERIC NON-ABUSE DETERRENT OPIOID DRUGS COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY. (3) AN INCREASE IN PATIENT COST-SHARING OR DISINCENTIVES FOR PRESCRI- BERS OR DISPENSERS SHALL NOT BE ALLOWED TO ACHIEVE COMPLIANCE WITH THIS SECTION. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.
By contributing or voting you agree to the Terms of Participation and verify you are over 13.